News & Views
Switching into Gene Therapy Expression
Jun 24 2022
Biotechnology company Flip Gene Therapeutics has signed an agreement with Aptamer Group to combine its inducible gene therapy platform with the use of Optimer binder technology.
Under the agreement Aptamer will develop binders to several small molecule targets for incorporation into the partner’s gene therapy platform with the goal of developing pharmacologically inducible gene therapeutics controllable with a gene switch.
Gene therapies treat diseases and conditions through the delivery of genetic material; however, major gene therapy platforms do not allow for precise control of gene expression after the therapy is administered.
Optimer binders used as a component of a gene switch could enable responsive gene expression controlled by dosing certain small molecule drugs.
The commercial terms of the agreement include initial upfront payments for Optimer development, with the potential for further licensing payments for the developed Optimer binders, and development and commercial milestone payments upon clinical and commercial success.
Dr Arron Tolley, CEO of Aptamer Group said: "I am delighted to have established this agreement to develop Optimer binders to enable inducible treatments in this exciting field of gene therapy. We will be working closely with our partner Flip Gene Therapeutics on developing and assessing the Optimer binders to function as part of their gene therapy platform. The interest in pursuing Optimer binders as part of their therapeutic modality offers a strong endorsement of the technology."
More information online
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia